PTPRD and non-small cell lung carcinoma: Among all the NSCLC patients, the objective response rate (ORR) was higher in the PTPRD mutation group than in the WT group (68% vs 15%, p <0.01, Fig. 2d), with concordant results in the ns-NSCLC subgroup (68% vs 14%, p <0.01, Fig. 2e).